{"analyses":[{"ciLowerLimit":"0.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.16","groupDescription":"For \\<5% PD-L1 expression. Ratio of Nivolumab over Investigator's Choice","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"1.13"},{"ciLowerLimit":"1.92","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"19.08","groupDescription":"For \\>=5% PD-L1 expression. Ratio of Nivolumab over Investigator's Choice","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"5.49"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"22.5","value":"15.3"},{"groupId":"OG001","lowerLimit":"6.1","upperLimit":"25.4","value":"13.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"title":"<5% PD-L1 expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.9","upperLimit":"53.0","value":"43.2"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"26.2","value":"12.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":">=5% PD-L1 expression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"267"},{"groupId":"OG001","value":"131"}],"units":"Participants"}],"description":"Objective Response Rate (ORR) is defined as the number of participants with a Best Overall Response (BOR) of complete response (CR) or partial response (PR) divided by number of randomized participants. PD-L1 expression evaluated for ORR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV over 60 minutes Q2W","id":"OG000","title":"Nivolumab"},{"description":"Dacarbazine: 1000 mg/m\\^2 IV Q3W Carboplatin: Area under the concentration-time curve (AUC) 6 IV Q3W Paclitaxel: 175 mg/m\\^2 IV Q3W","id":"OG001","title":"Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)"}],"paramType":"NUMBER","populationDescription":"All PD-L1 Evaluable Participants for ORR","reportingStatus":"POSTED","timeFrame":"From date of randomization to the date of objectively documented progression or the date of subsequent therapy (Up to approximately 38 months)","title":"Objective Response Rate (ORR) by Baseline PD-L1 Expression","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}